Hengrui Pharma(SH:600276) Xin Lang Ke Ji·2025-12-15 06:05Core Insights - The FZOCUS-1 study has been published in the prestigious journal "CA: A Cancer Journal for Clinicians," marking a significant milestone for clinical oncology research in China [1][2] - This study is the first clinical research in the field of gynecological oncology conducted by Chinese researchers to be featured in this top-tier journal [1] Study Overview - FZOCUS-1 is a randomized, double-blind, placebo-controlled Phase III clinical trial conducted over six years across 54 centers in China, involving 674 patients [1] - The study evaluates the efficacy and safety of the first domestically developed PARP inhibitor, Furazlopar, either alone or in combination with the anti-angiogenic drug Apatinib, for first-line maintenance treatment of advanced ovarian cancer [1] Key Findings - Patients receiving Furazlopar monotherapy achieved a median progression-free survival (PFS) of 29.9 months, showing a statistically significant difference compared to the placebo group [1] - In the subgroup of patients with BRCA mutations, the median PFS increased dramatically from 16.6 months in the placebo group to 47.8 months with Furazlopar monotherapy, significantly reducing the risk of disease progression or death [1] - The study confirmed that the use of PARP inhibitors alone can achieve ideal efficacy in HRD-positive populations, avoiding the side effects and economic burden associated with combination therapies [1] Industry Impact - The successful publication of the FZOCUS-1 study is seen as a vital contribution of "Chinese data" and "Chinese wisdom" to global ovarian cancer treatment practices [2] - The results reflect the commitment of the company, Heng Rui Medicine, to innovation and addressing global clinical challenges through independent research and development [2] - Furazlopar has been included in the medical insurance catalog, significantly improving drug accessibility for Chinese ovarian cancer patients [2]